NEW YORK (Reuters Health) Dec 22 - Paclitaxel and doxorubicin appear to have comparable efficacy in patients with metastatic angiosarcoma, researchers reported in Cancer.
Dr. Antoine Italiano of Institut Bergonie, Bordeaux, France and colleagues reviewed data on 75 patients who were treated with weekly paclitaxel and 42 who got weekly doxorubicin. Doxorubicin monotherapy is the first-line standard treatment, they said in a paper released online November 1st.
Thirty-four patients in the doxorubicin group and 68 in the paclitaxel group were evaluable. Doxorubicin and paclitaxel, respectively, produced complete responses in 6% and 13%, partial responses in 23.5% and 40%, stable disease rates of 29.5% and 29.5%, and progressive disease rates of 41% and 17.5%.
Patients with cutaneous angiosarcoma had more objective responses to paclitaxel, but tumor location did not affect response to doxorubicin.
Doxorubicin was associated with an objective response rate of 29.5% but a median progression-free survival of only three months. Paclitaxel was associated with an objective response rate of 53% and a longer median progression-free survival of 5.8 months.
Altogether, median progression-free survival was 4.9 months and overall survival was 8.5 months. Multivariate analysis showed that performance status (according to Eastern Cooperative Oncology Group criteria) was the sole independent predictor of outcome.
The researchers conclude that "the comorbidities and the preference of the patients should be considered for the choice of the chemotherapy regimen."
Dr. Italiano did not respond to requests for comments.
Dr. Antoine Italiano of Institut Bergonie, Bordeaux, France and colleagues reviewed data on 75 patients who were treated with weekly paclitaxel and 42 who got weekly doxorubicin. Doxorubicin monotherapy is the first-line standard treatment, they said in a paper released online November 1st.
Thirty-four patients in the doxorubicin group and 68 in the paclitaxel group were evaluable. Doxorubicin and paclitaxel, respectively, produced complete responses in 6% and 13%, partial responses in 23.5% and 40%, stable disease rates of 29.5% and 29.5%, and progressive disease rates of 41% and 17.5%.
Patients with cutaneous angiosarcoma had more objective responses to paclitaxel, but tumor location did not affect response to doxorubicin.
Doxorubicin was associated with an objective response rate of 29.5% but a median progression-free survival of only three months. Paclitaxel was associated with an objective response rate of 53% and a longer median progression-free survival of 5.8 months.
Altogether, median progression-free survival was 4.9 months and overall survival was 8.5 months. Multivariate analysis showed that performance status (according to Eastern Cooperative Oncology Group criteria) was the sole independent predictor of outcome.
The researchers conclude that "the comorbidities and the preference of the patients should be considered for the choice of the chemotherapy regimen."
Dr. Italiano did not respond to requests for comments.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου